|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Stoke Therapeutics, Inc. (STOK) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
47,587,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Stoke Therapeutics is a biotechnology company focused on treating the underlying causes of severe genetic diseases by upregulating protein expression. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Co. is developing antisense oligonucleotides to selectively restore protein levels. Co.'s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Co.'s second product candidate, STK-002, is in development for treatment of Autosomal Dominant Optic Atrophy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
3,721,728 |
3,741,728 |
3,773,676 |
3,848,676 |
| Total Sell Value |
$43,112,317 |
$43,217,660 |
$43,569,849 |
$44,323,692 |
| Total People Sold |
6 |
6 |
6 |
6 |
| Total Sell Transactions |
11 |
13 |
16 |
25 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Nash Huw M. |
COO & CBO |
• – – |
2021-08-02 |
4 |
OE |
$2.19 |
$12,483 |
D/D |
5,700 |
5,700 |
|
- |
|
| Ticho Barry |
Chief Medical Officer |
• – – |
2021-07-13 |
4 |
AS |
$32.68 |
$1,413,654 |
D/D |
(43,166) |
130,895 |
|
- |
|
| Nash Huw M. |
COO & CBO |
• – – |
2021-07-01 |
4 |
AS |
$33.33 |
$189,987 |
D/D |
(5,700) |
0 |
|
- |
|
| Nash Huw M. |
COO & CBO |
• – – |
2021-07-01 |
4 |
OE |
$2.19 |
$12,483 |
D/D |
5,700 |
5,700 |
|
- |
|
| Atp Iii Gp, Ltd. |
10% Owner |
– – • |
2021-06-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(17,161,713) |
0 |
|
- |
|
| Nash Huw M. |
COO & CBO |
• – – |
2021-06-01 |
4 |
AS |
$39.43 |
$22,669 |
D/D |
(575) |
0 |
|
- |
|
| Nash Huw M. |
COO & CBO |
• – – |
2021-06-01 |
4 |
OE |
$2.19 |
$1,259 |
D/D |
575 |
575 |
|
- |
|
| Liau Gene |
EVP Research & Preclinical Dev |
• – – |
2021-03-02 |
4 |
AS |
$62.46 |
$327,546 |
D/D |
(5,195) |
21,351 |
|
- |
|
| Liau Gene |
EVP Research & Preclinical Dev |
• – – |
2021-03-02 |
4 |
OE |
$0.60 |
$3,117 |
D/D |
5,195 |
26,546 |
|
- |
|
| Levin Arthur A |
Director |
– • – |
2021-03-01 |
4 |
AS |
$60.55 |
$759,841 |
D/D |
(12,500) |
0 |
|
- |
|
| Levin Arthur A |
Director |
– • – |
2021-03-01 |
4 |
OE |
$0.40 |
$6,576 |
D/D |
12,500 |
12,500 |
|
- |
|
| Tulipano Stephen J |
CFO |
• – – |
2021-02-23 |
4 |
AS |
$58.60 |
$292,992 |
D/D |
(5,000) |
602 |
|
- |
|
| Tulipano Stephen J |
CFO |
• – – |
2021-02-23 |
4 |
OE |
$4.48 |
$22,400 |
D/D |
5,000 |
5,602 |
|
- |
|
| Tulipano Stephen J |
CFO |
• – – |
2021-02-22 |
4 |
AS |
$58.67 |
$1,472,904 |
D/D |
(25,000) |
602 |
|
- |
|
| Tulipano Stephen J |
CFO |
• – – |
2021-02-22 |
4 |
OE |
$4.48 |
$112,000 |
D/D |
25,000 |
25,602 |
|
- |
|
| Tzianabos Arthur |
Director |
– • – |
2021-02-19 |
4 |
AS |
$60.67 |
$606,652 |
D/D |
(10,000) |
0 |
|
- |
|
| Tzianabos Arthur |
Director |
– • – |
2021-02-19 |
4 |
OE |
$2.19 |
$21,900 |
D/D |
10,000 |
10,000 |
|
- |
|
| Nash Huw M. |
COO & CBO |
• – – |
2021-01-06 |
4 |
AS |
$57.14 |
$1,828 |
D/D |
(32) |
0 |
|
- |
|
| Nash Huw M. |
COO & CBO |
• – – |
2021-01-04 |
4 |
AS |
$57.66 |
$336,157 |
D/D |
(5,700) |
32 |
|
- |
|
| Nash Huw M. |
COO & CBO |
• – – |
2021-01-04 |
4 |
OE |
$2.19 |
$12,483 |
D/D |
5,700 |
5,732 |
|
- |
|
| Liau Gene |
EVP Research & Preclinical Dev |
• – – |
2020-12-28 |
4 |
AS |
$58.73 |
$8,751 |
D/D |
(149) |
21,351 |
|
- |
|
| Liau Gene |
EVP Research & Preclinical Dev |
• – – |
2020-12-28 |
4 |
OE |
$0.60 |
$4,800 |
D/D |
8,000 |
21,500 |
|
- |
|
| Ticho Barry |
Chief Medical Officer |
• – – |
2020-12-21 |
4 |
AS |
$56.76 |
$78,654 |
D/D |
(1,365) |
173,402 |
|
- |
|
| Ticho Barry |
Chief Medical Officer |
• – – |
2020-12-21 |
4 |
OE |
$2.19 |
$2,989 |
D/D |
1,365 |
174,767 |
|
- |
|
| Nash Huw M. |
COO & CBO |
• – – |
2020-12-18 |
4 |
AS |
$60.00 |
$480,900 |
D/D |
(8,015) |
0 |
|
- |
|
149 Records found
|
|
Page 3 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
